Pheon Therapeutics Appoints Oncology Expert Arvin Yang, Md, Ph D As Chief Medical Officer

Oct 10, 2023•about 2 years ago

Position

Chief Medical Officer

Company

Pheon Therapeutics

Arvin Yang
LondonHealth CareTherapeuticsBiotechnology

Description

Pheon Therapeutics , a leading Antibody-Drug Conjugate company developing next generation ADCs for a wide range of hard-to-treat cancers, is pleased to announce the appointment of Arvin Yang, MD, PhD, as Chief Medical Officer.

Company Information

Company

Pheon Therapeutics

Location

London, England, United Kingdom

About

Pheon Therapeutics is an Antibody Drug Conjugate (ADC) specialist developing a pipeline of monotherapies for novel targets and/or with novel payloads. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. Pheon's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. Pheon is backed by expert, specialist healthcare investors Atlas Venture, Brandon Capital, Forbion and Research Corporation Technologies (RCT). Pheon has a world class, proven leadership team that brings together the best of ADC engineering, clinical and managerial expertise and track record. For further information, please visit www.pheontx.com

Related People

Sign in to view contact details

Sign in to view contact details

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months